We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Navigating the Diagnostic Overlap: Why 24 Percent of Patients Meeting Minimal MS Criteria for Optic Neuritis Require Antibody Testing

MedXY Editorial Team•Mar 18, 2026•Neurology
MOGADmultiple sclerosisNMOSDViêm thần kinh thị giác

Highlight

A recent multicenter retrospective study published in Neurology found that among patients presenting with inaugural acute optic neuritis who met the minimal 2017 McDonald criteria for multiple sclerosis (MS), 24% were ultimately diagnosed with an alternative antibody-mediated condition.

The study identified specific orbital MRI markers, including longitudinally extensive lesions, bilateral involvement, and optic perineuritis, as being 100% sensitive for non-MS diagnoses in this cohort.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Enhancing Diagnosis of AQP4-IgG+ NMOSD Myelitis: The Role of Novel and Established Spinal MRI SignsThis article evaluates spinal MRI features in AQP4-IgG+ NMOSD myelitis, highlighting the diagnostic specificity of bright spotty lesions, the double-contoured LETM sign, and sagittal ring enhancement for differentiating NMOSD from other myeSep 25, 2026Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated DiseaseIn pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highliAug 25, 2026Paramagnetic Rim Lesions as Predictors of Progression in Multiple Sclerosis: Insights from a 5-Year Longitudinal StudyParamagnetic rim lesions detected via MRI are associated with increased risk of disability progression independent of relapse activity and accelerated brain atrophy in multiple sclerosis, highlighting their role as prognostic biomarkers forAug 22, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores
Serum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI asses
Aug 21, 2026
Serum Glial Fibrillary Acidic Protein Dynamics in Multiple Sclerosis: Biomarker Insights into Disease Progression and Therapeutic ResponseSerum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.Aug 4, 2026
Assessing the Risk of CNS Demyelination Associated with TNF-α Inhibitors: Insights from a Large US Health NetworkA large retrospective study reveals a small but significant increase in CNS demyelination risk among patients treated with TNF-α inhibitors, varying by agent, with generally low absolute incidence.Jul 20, 2026